An individual-patient meta-analysis sheds light on the optimal duration of androgen deprivation therapy in men with prostate cancer on definitive radiotherapy.

A national clinical trial led by the Alliance for Clinical Trials in Oncology has found that oxybutynin, a drug often used to ...

A national clinical trial led by the Alliance for Clinical Trials in Oncology has found that oxybutynin, a drug often used to ...

J&J receives CHMP positive opinion for Akeega to treat patients with metastatic hormone-sensitive prostate cancer with BRCA1/2 mutations: Beerse, Belgium Monday, February 2, 2026, ...

—As more men are cured of prostate cancer, or are long-term survivors, the challenges of survivorship are in the spotlight. Improved screening practices, earlier detection, and better therapies have ...

Metformin did not prevent development of metabolic syndrome in men receiving androgen deprivation therapy for prostate cancer in a phase III trial. Metformin was associated with improvement in weight, ...

Men with prostate cancer who get hormone therapy experience hot flashes, where they experience intense and sudden heat and sweating. It can feel like a panic attack for some people before the heat ...

Italy: Patients with prostate cancer receiving maximal androgen blockade therapy face a significantly higher risk of bone ...

Prostate cancer (PCa) is one of the most common malignant tumors among men worldwide. Following androgen deprivation therapy ...